We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BDX Stock Gains 25.5% in Six Months: What's Behind the Rally?
Read MoreHide Full Article
Key Takeaways
BD shares have surged 25.5% in six months, fueled by portfolio reshaping and growth across platforms.
BDX raised its fiscal 2026 EPS outlook as strong free cash flow supported $3.1 billion in shareholder returns.
BD's product launches, clinical milestones and U.S. investment plan bolster growth despite tariff pressures.
Shares of Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, have gained 25.5% over the past six months, while its industry has advanced 17.6%. The stock's upward momentum is supported by improved execution after BD’s portfolio realignment, strength in high-growth businesses, and continued product innovation and clinical progress. Stronger shareholder returns and a new U.S. manufacturing agreement have further reinforced the investment case.
BDX is also scheduled to report fourth-quarter fiscal 2026 results on Nov. 5. The company is expected to beat on earnings with an Earnings ESP of 0.21%. Its earnings per share (EPS) estimate suggests 2.5% year-over-year growth despite a projected 13% decline in sales.
Image Source: Zacks Investment Research
Factors Supporting BDX’s Rally
A Focused Portfolio and Improving Earnings Visibility: BD’s third-quarter fiscal 2026 results provided fundamental support for the stock’s upward momentum.In its first full quarter of operations as “New BD” following the separation of its Life Sciences business, the company reported revenues of $5 billion, up 4.4%, while adjusted EPS of $3.23 surpassed expectations.
More than 90% of its portfolio delivered high-single-digit growth, while biologic drug delivery, advanced patient monitoring, PureWick and advanced tissue regeneration recorded double-digit growth.
The diversified portfolio matters because the company is increasingly relying on platforms operating in faster-growing markets rather than depending solely on mature medical supplies. Management raised its full-year adjusted EPS guidance to $12.62-$12.72, increasing the midpoint, while anticipating revenue growth near the upper end of its low-single-digit projection.
Year-to-date free cash flow reached $1.7 billion, up 45%, enabling BD to return approximately $3.1 billion to shareholders through repurchases and dividends. Improving execution, stronger earnings visibility and capital returns likely supported investor confidence.
Product Innovation Expands Commercial Opportunities: BD’s commercial initiatives have broadened the potential growth contribution from its portfolio. In May, the Wellstar Health System partnership linked Pyxis Pro dispensing technology with Alaris infusion systems, advancing connected medication management. Later that month, BD introduced the Elyra Thulium Fiber Laser System, expanding its urology portfolio.
In June, the CentroVena One insertion system received a Vizient Innovative Technology contract, potentially improving access to hospitals through a major purchasing network. In July, BD and EMS launched a semaglutide therapy in Brazil using BD’s Vystra injection pen, linking BD’s drug-delivery technology with expanding GLP-1 demand.
In September, BD reached a commercialization milestone when Fairview Health Services became the first U.S. health system to deploy its Vmax 160 pharmacy automation robot. Together, these developments support a more diversified growth narrative across drug delivery, procedural care and automation.
Clinical Progress and U.S. Manufacturing Strengthen the Outlook: BD also advanced its longer-term innovation pipeline. In August, enrollment was completed in the PREVENT trial, which evaluates Phasix Mesh for incisional hernia prevention. Later that month, the STANCE trial reached its first enrollment milestone for the GalaFLEX LITE scaffold, triggering an interim analysis. These milestones expand the evidence base for advanced tissue regeneration, although clinical and commercial outcomes are yet to be established.
In October, BD announced a major partnership with the U.S. government, outlining $19 billion in planned domestic investments over several years, including $3 billion toward manufacturing expansion. The agreement also offers potential relief from certain future Section 232 tariffs, contingent on implementation and the achievement of specified milestones. The following day, positive nine-month results from the AGILITY trial of the Revello vascular covered stent provided further clinical support for BD’s peripheral vascular pipeline. Together, these manufacturing and clinical developments could strengthen the company’s long-term growth prospects.
Concerns for BDX
Despite the positive momentum, BD continues to face execution risks and macroeconomic challenges. Management noted that tariff-related costs weighed on third-quarter adjusted operating margin by approximately 130 basis points, while expenses associated with resin, plastics and freight could remain volatile. Alaris remediation remains a defined drag, with a roughly 200-basis-point revenue headwind expected in fiscal 2027. Vaccine weakness in China persists, and several tissue-regeneration or vascular opportunities still depend on trial follow-up, regulatory pathways and commercial adoption.
BD’s rally reflects a more focused portfolio, improving execution and growing commercial validation across drug delivery, automation and interventional care. The U.S. manufacturing agreement and clinical milestones extend that growth narrative. Sustaining the advance, however, will require BD to scale its growth platforms while productivity, pricing and favorable product mix help offset legacy business pressures and tariffs.
Glaukos reported second-quarter 2026 earnings per share of 14 cents, which beat the Zacks Consensus Estimate by 50.00%. Revenues of $186 million surpassed the Zacks Consensus Estimate by 24.1%.
Glaukos has an estimated earnings growth rate of 268.8% for 2027. GKOS’ earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 25.87%.
Edward Lifesciences reported second-quarter 2026 adjusted EPS of 78 cents, which beat the Zacks Consensus Estimate by 6.85%. Revenues of $1.74 billion surpassed the Zacks Consensus Estimate by 2.45%.
Edward Lifesciences has an estimated long-term earnings growth rate of 12.7%. EW’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 4.49%.
Globus Medical reported a second-quarter fiscal 2026 adjusted EPS of $1.34, which beat the Zacks Consensus Estimate by 19.6%. Revenues of $790 million missed the Zacks Consensus Estimate by 0.35%.
Globus Medical has an estimated long-term earnings growth rate of 12.4%. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.88%.
View the Zacks #1 Rank List
Image: Bigstock
BDX Stock Gains 25.5% in Six Months: What's Behind the Rally?
Key Takeaways
Shares of Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, have gained 25.5% over the past six months, while its industry has advanced 17.6%. The stock's upward momentum is supported by improved execution after BD’s portfolio realignment, strength in high-growth businesses, and continued product innovation and clinical progress. Stronger shareholder returns and a new U.S. manufacturing agreement have further reinforced the investment case.
BDX is also scheduled to report fourth-quarter fiscal 2026 results on Nov. 5. The company is expected to beat on earnings with an Earnings ESP of 0.21%. Its earnings per share (EPS) estimate suggests 2.5% year-over-year growth despite a projected 13% decline in sales.
Image Source: Zacks Investment Research
Factors Supporting BDX’s Rally
A Focused Portfolio and Improving Earnings Visibility: BD’s third-quarter fiscal 2026 results provided fundamental support for the stock’s upward momentum.In its first full quarter of operations as “New BD” following the separation of its Life Sciences business, the company reported revenues of $5 billion, up 4.4%, while adjusted EPS of $3.23 surpassed expectations.
More than 90% of its portfolio delivered high-single-digit growth, while biologic drug delivery, advanced patient monitoring, PureWick and advanced tissue regeneration recorded double-digit growth.
The diversified portfolio matters because the company is increasingly relying on platforms operating in faster-growing markets rather than depending solely on mature medical supplies. Management raised its full-year adjusted EPS guidance to $12.62-$12.72, increasing the midpoint, while anticipating revenue growth near the upper end of its low-single-digit projection.
Year-to-date free cash flow reached $1.7 billion, up 45%, enabling BD to return approximately $3.1 billion to shareholders through repurchases and dividends. Improving execution, stronger earnings visibility and capital returns likely supported investor confidence.
Product Innovation Expands Commercial Opportunities: BD’s commercial initiatives have broadened the potential growth contribution from its portfolio. In May, the Wellstar Health System partnership linked Pyxis Pro dispensing technology with Alaris infusion systems, advancing connected medication management. Later that month, BD introduced the Elyra Thulium Fiber Laser System, expanding its urology portfolio.
In June, the CentroVena One insertion system received a Vizient Innovative Technology contract, potentially improving access to hospitals through a major purchasing network. In July, BD and EMS launched a semaglutide therapy in Brazil using BD’s Vystra injection pen, linking BD’s drug-delivery technology with expanding GLP-1 demand.
In September, BD reached a commercialization milestone when Fairview Health Services became the first U.S. health system to deploy its Vmax 160 pharmacy automation robot. Together, these developments support a more diversified growth narrative across drug delivery, procedural care and automation.
Clinical Progress and U.S. Manufacturing Strengthen the Outlook: BD also advanced its longer-term innovation pipeline. In August, enrollment was completed in the PREVENT trial, which evaluates Phasix Mesh for incisional hernia prevention. Later that month, the STANCE trial reached its first enrollment milestone for the GalaFLEX LITE scaffold, triggering an interim analysis. These milestones expand the evidence base for advanced tissue regeneration, although clinical and commercial outcomes are yet to be established.
In October, BD announced a major partnership with the U.S. government, outlining $19 billion in planned domestic investments over several years, including $3 billion toward manufacturing expansion. The agreement also offers potential relief from certain future Section 232 tariffs, contingent on implementation and the achievement of specified milestones. The following day, positive nine-month results from the AGILITY trial of the Revello vascular covered stent provided further clinical support for BD’s peripheral vascular pipeline. Together, these manufacturing and clinical developments could strengthen the company’s long-term growth prospects.
Concerns for BDX
Despite the positive momentum, BD continues to face execution risks and macroeconomic challenges. Management noted that tariff-related costs weighed on third-quarter adjusted operating margin by approximately 130 basis points, while expenses associated with resin, plastics and freight could remain volatile. Alaris remediation remains a defined drag, with a roughly 200-basis-point revenue headwind expected in fiscal 2027. Vaccine weakness in China persists, and several tissue-regeneration or vascular opportunities still depend on trial follow-up, regulatory pathways and commercial adoption.
Becton, Dickinson and Company Price and Consensus
Becton, Dickinson and Company price-consensus-chart | Becton, Dickinson and Company Quote
Conclusion
BD’s rally reflects a more focused portfolio, improving execution and growing commercial validation across drug delivery, automation and interventional care. The U.S. manufacturing agreement and clinical milestones extend that growth narrative. Sustaining the advance, however, will require BD to scale its growth platforms while productivity, pricing and favorable product mix help offset legacy business pressures and tariffs.
Zacks Rank & Other Key Picks
BD currently sports a Zacks Rank #1 (Strong Buy).
Some other top-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Edward Lifesciences (EW - Free Report) and Globus Medical (GMED - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Glaukos reported second-quarter 2026 earnings per share of 14 cents, which beat the Zacks Consensus Estimate by 50.00%. Revenues of $186 million surpassed the Zacks Consensus Estimate by 24.1%.
Glaukos has an estimated earnings growth rate of 268.8% for 2027. GKOS’ earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 25.87%.
Edward Lifesciences reported second-quarter 2026 adjusted EPS of 78 cents, which beat the Zacks Consensus Estimate by 6.85%. Revenues of $1.74 billion surpassed the Zacks Consensus Estimate by 2.45%.
Edward Lifesciences has an estimated long-term earnings growth rate of 12.7%. EW’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 4.49%.
Globus Medical reported a second-quarter fiscal 2026 adjusted EPS of $1.34, which beat the Zacks Consensus Estimate by 19.6%. Revenues of $790 million missed the Zacks Consensus Estimate by 0.35%.
Globus Medical has an estimated long-term earnings growth rate of 12.4%. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.88%.